A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer-Reference-Cited by-同舟云学术

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

Published:2017-07-05 Issue:3 Volume:165 Page:601-609
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Rugo Hope S.^ORCID,Trédan Olivier,Ro Jungsil,Morales Serafin M.,Campone Mario,Musolino Antonino,Afonso Noémia,Ferreira Marta,Park Kyong Hwa,Cortes Javier,Tan Antoinette R.,Blum Joanne L.,Eaton Lamar,Gause Christine K.,Wang Zhen,Im Ellie,Mauro David J.,Jones Mary Beth,Denker Andrew,Baselga José

Funder

Merck

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4375-5/fulltext.html

Reference28 articles.

1. Johnston SR (2006) Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 12:1061s–1068s

2. Burstein HJ (2011) Novel agents and future directions for refractory breast cancer. Semin Oncol 38(suppl 2):S17–S24

3. Quek R, Wang Q, Morgan JA et al (2011) Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17:871–879